Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has patented compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.
Laekna Therapeutics Shanghai Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Epics Therapeutics SA has described N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, infections, and neurological and inflammatory disorders.
Researchers from Allianthera Boston Inc. and Allianthera (Suzhou) Biopharmaceutical Co. Ltd. have prepared and tested serine/arginine-rich protein-specific kinase 1 (SRSF protein kinase 1; SRPK1) inhibitors reported to be useful for the treatment of cancer, inflammation, diabetes, age-related macular degeneration, obesity, arthritis, psoriasis and idiopathic pulmonary fibrosis.
Precision Biosciences Inc. has announced that its experimental allogeneic T cell therapy azercabtagene zapreleucel (azer-cel) for the treatment of multiple sclerosis (MS) has received IND clearance from the FDA.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with its BCMA-targeting CAR T cell SYS-6020 for systemic lupus erythematosus (lupus) in China.
Lantern Pharma Inc. has presented new data on their novel acylfulvene compound LP-184 as a DNA-damaging agent that induces DNA double-strand breaks (DNA DSBs) in cancer cells and may activate immune responses by activation of the cGAS/STING pathway.
AAT-076 was tested in the preclinical setting for its analgesic potential in COX-1 and COX-2 assays, as well as in in vivo rat models of air pouch inflammation, adjuvant-induced arthritis and neuropathic pain models. The compound was selected as a candidate analgesic compound due to its effective COX-2 inhibition within the central nervous system.
Halda Therapeutics Inc. announced it has secured an additional $126 million in funding in a series B extension, bringing its total funding to date to $202 million. The company expects its lead molecule HLD-0915 to enter a phase I trial in the first half of 2025 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Researchers at Rockefeller University have identified a signaling loop between breast cancer cells and sensory neurons that promoted tumor metastasis, and showed that in animal models, treatment with the approved anti-nausea medication aprepitant could disrupt that loop.
RSS
